FABIOR - (0.1% ; AEROSOL,FOAM)

Generic Name	TAZAROTENE	**Innovator**	Mayne Pharma
Dosage	0.1% ; AEROSOL,FOAM	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	Fabior Foam is a retinoid indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.